^
1d
Trial completion • Enrollment change
|
oxaliplatin
1d
Balloon-occluded hepatic arterial infusion for unresectable hepatocellular carcinoma: a phase II trial interim analysis. (PubMed, Front Oncol)
This phase II study (ChiCTR2300077718) aimed to assess the efficacy and safety of balloon-occluded HAIC (bHAIC) based on the FOLFOX (oxaliplatin plus fluorouracil and leucovorin) regimen (bHAIC-FO) in unresectable HCC. bHAIC-FO demonstrates encouraging efficacy and acceptable safety profiles in unresectable HCC treatment, particularly in treatment-naive patients. www.chictr.org.cn, identifier ChiCTR2300077718.
Clinical • P2 data • Journal
|
AFP (Alpha-fetoprotein)
|
AFP elevation
|
5-fluorouracil • oxaliplatin • leucovorin calcium
3d
Network Pharmacology and Experimental Validation to Explore the Potential Mechanism of Salvianolic Acid B in Reversing Oxaliplatin Resistance of Colorectal Cancer Cells. (PubMed, IET Syst Biol)
In conclusion, SalB modulates CRC drug resistance through multiple targets and pathways. SalB potentially reverses oxaliplatin resistance in CRC cells by regulating the ROS-mediated apoptotic signalling pathway.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9)
|
oxaliplatin
4d
Efficacy and safety of TiaoPi AnChang decoction to reduce CAPOX-Induced adverse reactions in Chinese patients with colorectal cancer: a randomized, double-blind, placebo-controlled trial. (PubMed, Front Pharmacol)
TPACD administration resulted in improvements in symptoms including fatigue, nausea, vomiting, loss of appetite, and oxaliplatin-induced peripheral neuropathy...TPACD serves as an effective, safe, well-tolerated, and readily acceptable complementary therapy for CRC patients undergoing CAPOX. https://www.chictr.org.cn/index.html, identifier ChiCTR2200065759.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
|
oxaliplatin
7d
TELO2-interacting protein 1 (TTI1), a novel Wnt/β-catenin target gene, decreases chemo-sensitivity in colorectal cancer by modulating DNA damage responses. (PubMed, Mol Biomed)
Genetic depletion of TTI1 destabilizes ATM and ATR, attenuates DNA damage signaling, impairs double-strand break repair, and sensitizes colorectal cancer cells to 5-fluorouracil and oxaliplatin. These findings define a β-catenin-TTI1-ATM/ATR axis that links Wnt/β-catenin activation to DNA damage tolerance and chemotherapy response in colorectal cancer. Targeting TTI1 is therefore a promising approach to improve chemotherapy efficacy in Wnt/β-catenin-activated colorectal cancer.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway) • ATR (Ataxia telangiectasia and Rad3-related protein)
|
5-fluorouracil • oxaliplatin
11d
Protective Effect of Lycopene Against Oxaliplatin-Induced Nephrotoxicity by Modulation NF-κB/TNF-α/IL-1β, P53/Bax/Bcl2, and PI3K/AKT/mTOR Signaling Pathway. (PubMed, J Biochem Mol Toxicol)
LP treatment ameliorated these pathological alterations by restoring antioxidant enzyme activities, downregulating proinflammatory and proapoptotic signals, mitigating ER stress and autophagy activation, and reducing PI3K/AKT/mTOR protein expression. These findings demonstrate that LP exerts a renoprotective effect against OXI-induced kidney injury through multi-targeted molecular mechanisms, including modulation of inflammation, oxidative stress, autophagy, apoptosis, and survival signaling pathways.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • mTOR (Mechanistic target of rapamycin kinase) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ATF6 (Activating Transcription Factor 6) • IL1B (Interleukin 1, beta) • BECN1 (Beclin 1) • PI3K (Phosphoinositide 3-kinases)
|
oxaliplatin
11d
Comparison of pharmacovigilance and mechanism analysis of the vascular toxicity caused by platin-based chemotherapy: integration of FAERS analysis, network pharmacology, and endothelial validation. (PubMed, Ther Adv Drug Saf)
This study comprehensively identifies the vessel-threatening effects of cisplatin (CDDP), carboplatin (CBP), and oxaliplatin (OXA) and aims to compile an analytical model. The results suggest activation of the oxidative stress pathway through Nrf2 inhibition and increased ICAM1 levels, alongside pathway‑specific alterations such as reduced HIF1A and NOS3 expression and decreased VCAM1 levels. Early cardiovascular monitoring and Nrf2‑targeted therapy warrant further investigation.
Journal • Adverse events
|
EGFR (Epidermal growth factor receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • ICAM1 (Intercellular adhesion molecule 1) • NOS3 (Nitric oxide synthase 3) • VCAM1 (Vascular Cell Adhesion Molecule 1)
|
cisplatin • carboplatin • oxaliplatin
11d
An explainable predictive machine learning model of oxaliplatin induced peripheral neuropathy based on clinical data: a retrospective single center. (PubMed, Support Care Cancer)
This study demonstrates that the GBDT machine learning model effectively predicts OIPN risk in colorectal cancer patients. Combined with SHAP analysis, the model's interpretability is enhanced. The developed online calculator provides a reliable tool for early clinical identification of high-risk patients and personalized intervention strategies.
Clinical data • Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • APOA1 (Apolipoprotein A-I)
|
oxaliplatin
11d
Prostate brachytherapy followed by secondary urethral adenocarcinoma: A case report. (PubMed, Urol Case Rep)
After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 amplification
|
capecitabine • oxaliplatin
14d
Management of locally advanced lynch syndrome rectal cancer during pregnancy with neoadjuvant immunochemotherapy: a case report. (PubMed, Front Oncol)
The patient subsequently underwent neoadjuvant chemoradiotherapy (50.4 Gy in 28 fractions) combined with two cycles of capecitabine plus oxaliplatin (CapeOx) and tislelizumab, achieving significant tumor regression (yT2N0M0). LS-associated rectal cancer during pregnancy requires individualized, multidisciplinary management. Medical termination followed by neoadjuvant immunochemoradiotherapy can optimize maternal outcomes while minimizing fetal and genetic risks.
Journal
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
|
Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
14d
Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. (PubMed, Jpn J Clin Oncol)
Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Opdivo (nivolumab) • Cyramza (ramucirumab) • oxaliplatin
15d
A feasibility randomised controlled trial of water-only fasting prior to CAPOX chemotherapy for stage 2/3 colorectal cancer. (PubMed, Pilot Feasibility Stud)
The SWiFT study was feasible to deliver and adherence to the fast was high. In a future definitive trial, success in recruitment appears to depend more on specific local factors rather than the intervention being unattractive to most potential participants.
Journal
|
IGF1 (Insulin-like growth factor 1) • IGFBP2 (Insulin-like growth factor binding protein 2) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
capecitabine • oxaliplatin